The roots of modern robotic surgery can be traced back to US Department of Defense-funded research focused on applications for battlefield telesurgery. Following a period of commercial development, legal battles, and industry consolidation, robotic surgery has matured and expanded across a variety of disciplines. Yet there is still uncertainty regarding the value generated by this proliferation. In this issue of CHEST (see page 1505), Paul and colleagues1 add to the growing literature on robotic technology in thoracic surgery. They identify several important findings. First, robotic lobectomy volume increased substantially over their study period. Second, when compared with an established minimally invasive platform, video-assisted thoracoscopic surgery (VATS), robotic lobectomy was associated with more intraoperative hemorrhage and iatrogenic injury and cost, yet offered no clinical benefit.